ClinicalTrials.gov term: Leukemia, Myeloid, Acute

Disease landscape

Acute Myeloid Leukemia (AML) clinical trials

Get alerts when Acute Myeloid Leukemia (AML) trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

95 trials changed in the last 30 days: 8 stopped, 32 with notable changes, 55 with minor changes only.

  1. Stopped

    BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax · Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Trial terminated

    Also in this update: Trial sites reduced: 16 → 10 locations; Primary completion date changed from estimate of Feb 1, 2027 to Aug 28, 2026

    Bristol-Myers SquibbPhase 1 NCT06419634 Registry history of NCT06419634 on ClinicalTrials.gov (opens the registry)

  2. Notable

    Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant · Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

    Primary and study completion pushed from Apr 5, 2029 to Nov 5, 2031

    City of Hope Medical CenterPhase 2 NCT07582172 Registry history of NCT07582172 on ClinicalTrials.gov (opens the registry)

Show 55 trials with minor changes only
  1. Minor

    VERO · Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

    Trial completed

    Also in this update: Primary completion date changed from estimate of Nov 2026 to Jul 21, 2026

    AbbVieNot specified NCT06058741 Registry history of NCT06058741 on ClinicalTrials.gov (opens the registry)

  2. Minor

    Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

    Enrollment closed, study ongoing

    Also in this update: Enrollment reduced: 77 → 60 participants; Primary completion date changed from estimate of Dec 1, 2026 to Jul 31, 2026

    The First Affiliated Hospital of Soochow UniversityPhase 2 NCT06379360 Registry history of NCT06379360 on ClinicalTrials.gov (opens the registry)

  3. Minor

    Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

    Trial sites expanded: 68 → 71 locations

    And 1 more change in the last 30 days

    National Cancer Institute (NCI)Phase 2 NCT06917911 Registry history of NCT06917911 on ClinicalTrials.gov (opens the registry)

  4. Minor
    5 trials marked Unknown by the registry's verification sweep
    1. Minor

      Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen · Intermediate/Adverse Risk or Persistently Positive MRD AML

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

      Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT06758726 Registry history of NCT06758726 on ClinicalTrials.gov (opens the registry)

      Changed

    2. Minor

      Immune-AML · Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

      Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting

      Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNot specified NCT03789981 Registry history of NCT03789981 on ClinicalTrials.gov (opens the registry)

      Changed

    Registry verification sweep

    Changed

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-16 NCT07877610 CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults Fondazione Matilde Tettamanti Menotti De Marchi Onlus new Phase 1/2
2026-10-14 NCT07874100 This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to… Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new
2026-10-09 NCT07867600 Low Dose Induction for Pediatric Acute Myeloid Leukemia Patients Azza Shibl Sayed new
2026-10-06 NCT07861477 Murottal as Adjunctive Intervention in Pediatric Universitas Airlangga new
2026-09-17 NCT07826897 Real-Time Breath Analysis in Acute Myeloid Leukaemia for a Rapid Characterisation of… Jeremy Deuel new
2026-09-10 NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… University of West Attica new
2026-09-09 NCT07809906 Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression Orum Therapeutics USA, Inc. new Phase 1
2026-09-04 NCT07805096 Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and… National Defense Medical University, Taiwan new
2026-09-03 NCT07802015 Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish… Zealand University Hospital new
2026-08-19 NCT07773909 Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive… Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh new Phase 4

Active trials by phase

Early Phase 1
25
Phase 1
267
Phase 1/2
129
Phase 2
282
Phase 2/3
29
Phase 3
72
Phase 4
9
Not charted: 228 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Top sponsors by active trials in this area

Get alerts when Acute Myeloid Leukemia (AML) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials